QIAGEN Reaffirms FY24 Sales Of At Least $1.985B Vs $1.98B Est.; Increases EPS Guidance From $2.10 CER To At Least $2.19 CER Vs $2.15 Est.
QIAGEN Reaffirms FY24 Sales Of At Least $1.985B Vs $1.98B Est.; Increases EPS Guidance From $2.10 CER To At Least $2.19 CER Vs $2.15 Est.
QIAGEN重申FY24銷售額至少爲19.85億美元，預估爲19.8億美元；每股收益指引從2.10美元CER提高至至少2.19美元CER，預估爲2.15美元。
QIAGEN has reaffirmed its FY 2024 sales outlook for at least $1.985 billion CER based on the solid core business performance in the first nine months of the year. The outlook for adjusted diluted EPS has been increased to at least $2.19 CER (previously $2.10 CER at start of 2024), while the adjusted operating income margin target has been reaffirmed for at least 28.5% compared to 26.9% in 2023.
QIAGEN已確認2024年財年銷售展望至少爲19.85億美元（以本年首九個月穩健的核心業務表現爲基礎）。調整後的攤薄後每股收益展望已調高至至少2.19美元（此前2024年起點爲2.10美元），而調整後的營業利潤率目標已確認至少爲28.5%，較2023年的26.9%有所提升。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間